GlassScriptPhysician profile
Carolyn Joy Green
NPI 1972876738
$4,580.59
in general payments reported to CMS, 2019-2025
19 companies · $1,784 in 2025
The $1,784 reported for 2025 was more than what 91% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $123 · 2023: $1,596 · 2024: $1,078 · 2025: $1,784.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,286 · Travel and Lodging: $1,037 · Education: $135.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,285.91 |
| Travel and Lodging | $1,037.07 |
| Education | $134.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $1,718.52 | 2022-2023 | Inspire |
| Genzyme Corporation | $523.51 | 2024-2025 | |
| Glaxosmithkline, LLC. | $410.02 | 2024-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Regeneron Healthcare Solutions, INC. | $396.98 | 2024-2025 | Dupixent |
| Insmed, INC. | $254.17 | 2024-2025 | Arikayce, Brinsupri |
| Astrazeneca Pharmaceuticals LP | $230.11 | 2024-2025 | Tezspire, Fasenra, Airsupra |
| United Therapeutics Corporation | $211.73 | 2024-2025 | Tyvaso, Tyvaso |
| Electromed, INC. | $195.27 | 2024-2025 | Smartvest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $129.81 | 2024 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Grifols USA, LLC | $124.94 | 2024-2025 | Prolastin-C Liquid |
| Amgen INC. | $110.52 | 2024-2025 | Tezspire |
| Sanofi-Aventis U.S. LLC | $99.95 | 2025 | |
| Lilly USA, LLC | $50.25 | 2025 | Zepbound, Mounjaro |
| Harmony Biosciences LLC | $26.59 | 2024 | |
| Verona Pharma, INC. | $24.13 | 2025 | Ohtuvayre |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $21.63 | 2024 | |
| Merck Sharp & Dohme LLC | $18.32 | 2024 | |
| Noctrix Health, INC. | $18.14 | 2025 | Nidra |
| Viatris Specialty LLC | $16.00 | 2025 | Yupelri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carolyn Green listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.